Super User

Super User

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Wednesday, 25 April 2018 18:59

Alona Tal

Manager of Quality Assurance. Alona joined the Company in 2011 as a Research Associate. As of 2017 she serves as a head of QA department. Alona holds a B.Sc. in Biotechnology from Hadassah Academic College and M.Sc. in Genetics from Hebrew University in Jerusalem.

 

Sunday, 04 March 2018 07:06

EYAL LOUZON

Manager of Operations. Eyal has joined the company in 2011. He is managing the company’s Supply chain, facilities and information systems. Eyal has brought to the company an extensive work experience of more than 10 years in various operations related positions. Prior to joining Immunovative Eyal was engaged as a production planner in the Industrial engineering department at Ophir Optronics. He has also led a manufacturing team in Intel Corporation. Eyal has a B.Sc. in Life Science from Ben-Gurion University and a M.Sc. in Technology Management from the Faculty of science and the Business School of the Hebrew University.

 

Abstract poster from ASCO 2018 Cancers Symposium on the AlloVax Phase I/II Trial for Head and Neck Squamous Cell Carcinoma

Abstract poster from ASCO 2018 Gastrointestinal Cancers Symposium on the CryoVax Phase I/IIb Trial: In-Situ vaccine for Metastatic Colorectal Cancer

Abstract poster from ASCO 2018 Gastrointestinal Cancers Symposium on the AlloVax Phase II trial of personalized vaccine for advanced Hepatocellular Carcinoma

Wednesday, 20 December 2017 09:23

Full List of Granted Patents

Serial Number Country Title Status Date Granted Patent No
11/069,010 US T-Cell Therapy Formulation Granted 22/07/08 7402431
10/838,454 US Compositions for Allogeneic Cell Therapy Granted 14/10/08 7435592
11/601,446 US Biodegradable T-Cell Activation Device and Method Granted 22/09/09 7592431
11/066,133 US Methods for Preparing T-Cells for Cell Therapy Granted 16/03/10 7678572
12/172,594 US A Method for Stimulating a Host Immune System by Granted 17/05/11 7943180
12/687,281 US Device for Enhancing Immunostimulatory Capabilities of T-Cells Granted 07/06/11 7956164
11/936,948 US Ablative Immunotherapy Granted 05/07/11 7972594
12/533,668 US Biodegradable T-Cell Activation Method Granted 06/09/11 8012750
12/817,512 US Methods for Preparing T-Cells for Cell Therapy Granted 06/12/11 8071374
12/173,330 US Method of Preparing a Treatment Effective Amount Granted 13/12/11 8076135
12/869,490 US A Method for Allogeneic Cell Therapy Granted 25/09/12 8273377
13/099,871 US Method for Stimulating a Therapeutic Immune Effect Granted 30/10/12 8298587
13/187,991 US Methods to Cause Differentiation of T-Cells Granted 20/11/12 8313944
12/909,517 US Allogeneic Cell Compositions that Elicit Type I Granted 15/01/13 8354276
13/596,142 US A Method for Allogeneic Cell Therapy Granted 25/03/14 8679841
13/099,867 US Method for Stimulating a Host Immune System Granted 20/05/14 8728534
12/887,054 US Composition of Activated CD4 Cells Granted 15/07/14 8778678
12/887,054 US Composition of Activated CD4 Cells Granted 15/07/14 8778678
12/887,039 US Method to Formulate T-Cells Granted 22/07/14 8785188
11/251,585 US Allogeneic Cellular Immunotherapy for Invasive Pulmonary Aspergillosis (IPA) Granted 21/10/14 8,865,224
13/077,347 US A Device for Enhancing Immunostimulatory Capabilities of T-Cells Granted 11/11/14 8883974
13/581745 US Induction of IL-12 using immunotherapy Granted 12/01/16 9233156
13/150,893 US Ablative Immunotherapy Granted 01/03/16 9272001
14/173,494 US Method for Allogeneic Cell Therapy Granted 05/04/16 9301977
13/796,171 US Ablative Immunotherapy Granted 26/04/16 9320794
14/206,785 US Method for Stimulating a Host Immune System Granted 31/05/16 9352001
14/301,700 US Method to Formulate T-Cells Granted 06/12/16 9511127
14/500,381 US Device for Enhancing Immunostimulatory Capabilities of T-Cells Granted 14/03/17 9593308
12/570,442 US Th 1 Vaccination Priming for Active Immunotherapy Granted 04/07/17 9695397
15/041642 US Method for Allogeneic Cell Therapy Granted 10/10/17 9782463
102107555  Taiwan Automated Device for A Biologic Drug Distrubtion Granted 11/01/18 I610861
12010502709 Philippines Chaperone Proteins and Allogeneic T-Cells Granted 09/05/17 1-2010-502709
1020107027043 Korea Chaperone Proteins and Allogeneic T-Cells Granted 19/12/16 10-1689210
2007-501882 Japan Cell Therapy Formulation Method and Composition Granted 30/11/12 5144250
2009-505345 Japan Allogeneic Cell Therapy for Treatment of Opportunistic Infection Granted 26/04/13 5254952
2009-536306 Japan Ablative Immunotherapy Granted 14/03/14 5498792
2011-236442 Japan Cell Therapy Formulation Method and Composition Granted 21/11/14 5649551
2011507708 Japan Chaperone Proteins and Allogeneic T-Cells Granted 13/03/15 5709264
2014-509383 Japan Methods for Handling Biological Drugs Containing Living Cells Granted 13/05/16 5934783
2014-266252 Japan Flexible Container or Syringe Granted 16/09/16 6006288
2010-232031 Japan Allogeneic Cell Therapy: Mirror Effect Granted 28/10/16 6030819
2013-241607 Japan Methods for Preparing T-Cells for Cell Therapy Granted 28/10/16 6031021
2011-530213 Japan Pre-Vaccinations in Active Immunotherapy Granted 20/12/16 6042065
2013-526060 Japan Cells Expressing TH1 Characteristics and Cytolytic Properties Allowed    
173405 Israel Compositions for Infusion Containing Ex-Vivo Prepared T-Cells  Granted 29/05/11 06/10/74
198782 Israel Biodegradable T-cell Activation Device and Methods Granted 03/01/13 198782
171850 Israel Allogeneic Cell Therapy: Mirror Effect Granted 28/05/14 171850
194667 Israel Allogeneic Cell Therapy for Treatment of Opportunistic Infection Granted 01/10/15 194667
198704 Israel Ablative Immunotherapy Granted 01/10/15 198704
212102 Israel Pre-Vaccinations in Active Immunotherapy Granted 01/10/16 212102
177404 Israel Methods for Preparing T-Cells for Cell Therapy Granted 30/03/17 177404
W-00201204692 Indonesia Methods and Compositions for Inhibiiton of Treg Cells Granted 30/03/16 IDP000040595
13111030.4 Hong Kong Methods and Compositions for Inhibition of Treg Cells Granted 29/01/16 HK1184362 
5724065.7 Europe Cell Therapy Formulation Method and Composition Granted 17/05/17 1749090
9818495.5 Europe Pre-Vaccinations in Active Immunotherapy Granted 31/05/17 2334309
12779413.9 Europe Methods for Handling Biological Drugs Containing Living Cells Granted 23/08/17 2704741
11818884.6 Europe Cells Expressing TH1 Characteristics and Cytolytic Properties Granted 22/11/17 2606125
12177732 EPO  Method for Preparing T-Cells for Cell Therapy Granted 11/05/16 2573166
6750196.5 EPO Allogeneic Cell Therapy for Treatment of Opportunistic Infection Granted 11/06/14 2003978
2009801477496 China Pre-Vaccinations in Active Immunotherapy Granted 25/03/15 ZL200980147749.6
201180019282 China Methods and Compositions for Inhibition of Treg Cells Granted 23/09/15 ZL201180019282.4
201510137977 China Th1 Vaccination Priming for Active Immunotherapy Granted 22/09/17 ZL201510137976.8
2555714 Canada Methods for Preparing T-Cells for Cell Therapy Granted 03/12/13 2555714
2530513 Canada Cell Therapy Formulation Method and Composition Granted 31/01/17 2530514
2649290 Canada Allogeneic Cell Therapy for Treatment of Opportunistic Infection Granted 04/04/17 2649290
2669315 Canada Therapeutic Compositions With Lysates and T-Cells for Tumors or Pathogen Infected Tissue Granted 12/12/17 2669315
2009242471 Australia Chaperone Proteins and Allogeneic T-Cells Granted 24/09/15 2009242471
2012250794 Australia Methods for Handling Biological Drugs Containing Living Cells Granted 18/02/16 2012250794
2011240752 Australia Methods and Compositions for Inhibition of Treg Cells Granted 10/11/16 2011240752
2011291477 Australia Cells Expressing TH1 Characteristics and Cytolytic Properties Granted 10/11/16 2011291477
2016231642 (Divisional of 2011240752) Australia Methods and Compositions for Inhibition of Treg Cells Granted 19/07/18 2016231642
Thursday, 24 November 2016 16:52

DGANIT COHEN

Director of Human Resources. Dganit joined Immunovative Therapies in 2016 and has over 10 years of experience in Human Resources in her previous role in Ophir Optronics Teva. She provided guidance and leadership to senior managers in international organizations through various stages of growth and stabilization. Additionally, she has considerable experience in management, training, career development and employee relations. Dganit holds a Masters Degree in Anthropology from the Hebrew University in Jerusalem. And a Bachelors Degree in Human Resource from Ben Gurion University

CryoVax® is being tested to determine if this next generation immunotherapy can overcome the limited efficacy of immunotherapy in mCRC.  

Jerusalem, Israel – November 7, 2016—Immunovative Therapies, Ltd., on behalf of its’ subsidiary, ImmunoCare, Ltd., today announced the start of a Phase IIb study of CryoVax®, a next generation immunotherapy cancer vaccine product, for patients with chemotherapy-refractory (third line) metastatic colorectal cancer (mCRC). The trial is being conducted by Banner MD Anderson Medical Center, in Phoenix, AZ, which is partnered with the world renowned  University of Texas MD Anderson Cancer Center in Houston, TX, Recruitment in the trial is underway, and the first volunteers have received their initial vaccine doses. Enrollment is expected to be completed by the end of July 2017.

Immunovative today announces that it has released its first batch of AlloStim produced with blood collected in compliance with 21 CFR 1271 regulations.  These cells will be used in our Phase II clinical trial in metastatic colorectal cancer being conducted at Banner-MD Anderson Medical Center in Phoenix, AZ.

Immunovative's wholly-owned subsidiary, Immunovative Clinical Research, Inc. (ICRI) in Phoenix, AZ announces that its blood donor screening, collection, testing , processing and shipping operations have passed a baseline independent audit as being in compliance with 21 CFR 1271 (GTP)regulations.  CGTP requirements govern the methods used in, and the facilities and controls used for, the manufacture of biological products derived from blood.

Page 1 of 10

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more